Celgene beats on earnings, despite decline in U.S. Revlimid sales

Celgene's ($CELG) earnings topped expectations for the first quarter, as its blood-cancer drug Revlimid continued to deliver double-digit sales growth. The company's leading drug, Revlimid brought in $1.14 billion for the period, up 14%, despite a decline in the U.S. Its newer cancer treatment, Abraxane, fell short of expectations, however; though up 51%, the drug's $185 million missed estimates of $212 million. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…